CD274 and neoplasm: Studies examining the impact of IO agents on certain high-grade neuroendocrine (HG-NEN) tumors have shown mixed results raising questions related to the predictive/prognostic value of PD-1/PD-L1 expression alone for IO deployment and side-effect management (54).